EP1539931A4 - Differentiation modulating agents and uses therefor - Google Patents

Differentiation modulating agents and uses therefor

Info

Publication number
EP1539931A4
EP1539931A4 EP03735152A EP03735152A EP1539931A4 EP 1539931 A4 EP1539931 A4 EP 1539931A4 EP 03735152 A EP03735152 A EP 03735152A EP 03735152 A EP03735152 A EP 03735152A EP 1539931 A4 EP1539931 A4 EP 1539931A4
Authority
EP
European Patent Office
Prior art keywords
modulating agents
uses therefor
differentiation modulating
differentiation
therefor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03735152A
Other languages
German (de)
French (fr)
Other versions
EP1539931A1 (en
Inventor
Johannes Bernhard Prins
Louise Joyce Hutley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verva Pharmaceuticals Pty Ltd
Original Assignee
University of Queensland UQ
Queensland Institute of Medical Research QIMR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Queensland UQ, Queensland Institute of Medical Research QIMR filed Critical University of Queensland UQ
Priority to EP10184571A priority Critical patent/EP2267117A3/en
Publication of EP1539931A1 publication Critical patent/EP1539931A1/en
Publication of EP1539931A4 publication Critical patent/EP1539931A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0653—Adipocytes; Adipose tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/28—Vascular endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
EP03735152A 2002-06-27 2003-06-27 Differentiation modulating agents and uses therefor Withdrawn EP1539931A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10184571A EP2267117A3 (en) 2002-06-27 2003-06-27 Differentiation modulating agents and uses therefor

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39213002P 2002-06-27 2002-06-27
US392130P 2002-06-27
PCT/AU2003/000826 WO2004003179A1 (en) 2002-06-27 2003-06-27 Differentiation modulating agents and uses therefor

Publications (2)

Publication Number Publication Date
EP1539931A1 EP1539931A1 (en) 2005-06-15
EP1539931A4 true EP1539931A4 (en) 2006-08-23

Family

ID=30000816

Family Applications (2)

Application Number Title Priority Date Filing Date
EP10184571A Withdrawn EP2267117A3 (en) 2002-06-27 2003-06-27 Differentiation modulating agents and uses therefor
EP03735152A Withdrawn EP1539931A4 (en) 2002-06-27 2003-06-27 Differentiation modulating agents and uses therefor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP10184571A Withdrawn EP2267117A3 (en) 2002-06-27 2003-06-27 Differentiation modulating agents and uses therefor

Country Status (7)

Country Link
EP (2) EP2267117A3 (en)
JP (2) JP2005535629A (en)
CN (1) CN1678734B (en)
AU (2) AU2003236557B2 (en)
CA (1) CA2490261A1 (en)
NZ (1) NZ537208A (en)
WO (1) WO2004003179A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2490261A1 (en) * 2002-06-27 2004-01-08 The University Of Queensland Differentiation modulating agents and uses therefor
CA2542638A1 (en) * 2003-10-16 2005-04-28 Imclone Systems Incorporated Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
WO2005093083A1 (en) * 2004-03-29 2005-10-06 Kazuhisa Maeda Method of disease prediction and method of using the same
WO2006132447A1 (en) * 2005-06-10 2006-12-14 Primary Cell Co., Ltd. Method of inducing differentiation from visceral preadipocyte to visceral adipocyte
GB0520063D0 (en) * 2005-10-03 2005-11-09 Novartis Forschungsstiftung Methods for regulating metabolism and diagnosing disease
US7946916B2 (en) 2006-01-12 2011-05-24 Waterleaf Ltd. Variable payout wager games
CN101058801B (en) * 2007-04-13 2010-05-19 中国人民解放军第二军医大学 Method of accelerating human hypodermic fat stem cell differentiation and maturation and application thereof
EP2215102B1 (en) 2007-10-01 2016-02-17 Ionis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
CN101259266B (en) * 2008-04-14 2010-04-14 山东大学 Preadipocyte heterologous vaccine and preparation method and application thereof
US20130116171A1 (en) * 2010-04-16 2013-05-09 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf
CN103597074A (en) 2011-06-16 2014-02-19 Isis制药公司 Antisense modulation of fibroblast growth factor receptor 4 expression
US9446096B2 (en) 2011-12-30 2016-09-20 Joslin Diabetes Center, Inc. Glypican-4 based compositions and methods for treating and diagnosing insulin resistance
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
CA3205855A1 (en) 2013-04-16 2014-10-23 Orbsen Therapeutics Limited Medical use of syndecan-2
MX2016005101A (en) 2013-10-21 2017-01-09 Salk Inst For Biological Studi Mutated fibroblast growth factor (fgf) 1 and methods of use.
WO2015061331A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
US20170065678A1 (en) 2014-03-11 2017-03-09 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
JP6920207B2 (en) 2015-03-20 2021-08-18 オルブセン セラピューティクス リミテッド Cindecan-2 modulator and its use
WO2016172290A1 (en) * 2015-04-21 2016-10-27 Salk Institute For Biological Studies Methods of treating lipodystrophy using fgf-1 compounds
AU2016344134A1 (en) 2015-10-30 2018-05-31 Salk Institute For Biological Studies Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs
EP3922253A1 (en) 2016-01-15 2021-12-15 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use
AU2018300272A1 (en) 2017-07-14 2020-02-06 Orbsen Therapeutics Limited CD39 stromal stem cells methods of isolation and use
US20210401728A1 (en) * 2018-10-26 2021-12-30 Ivan GALANIN Topical Compositions and Methods to Promote Optimal Dermal White Adipose Tissue Composition in Vivo
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose
BR112023002455A2 (en) 2020-08-21 2023-03-28 Genzyme Corp FGFR3 ANTIBODIES AND METHODS OF USE

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0420081A1 (en) * 1989-09-26 1991-04-03 Takeda Chemical Industries, Ltd. Monoclonal antibody against an acidic FGF protein, its production and use
WO2000071129A1 (en) * 1999-05-21 2000-11-30 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
WO2001049849A1 (en) * 2000-01-05 2001-07-12 Zymogenetics, Inc. Novel fgf homolog zfgf11
WO2001070977A2 (en) * 2000-03-22 2001-09-27 Amgen, Inc. Fibroblast growth factor receptor-like molecules and uses thereof
EP1202065A1 (en) * 2000-10-25 2002-05-02 Aventis Pharma S.A. Net, a transcription factor of the TCF family, as regulator of angiogenic expression.
WO2003099796A1 (en) * 2002-05-23 2003-12-04 Cytopia Pty Ltd Protein kinase inhibitors
WO2004001059A2 (en) * 2002-06-20 2003-12-31 Bristol-Myers Squibb Company Heterocyclic inhibitors of kinases

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US424279A (en) 1890-03-25 Supporting wheel or pulley
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4849338A (en) 1982-07-16 1989-07-18 Syntex (U.S.A.) Inc. Simultaneous calibration heterogeneous immunoassay
US4843000A (en) 1979-12-26 1989-06-27 Syntex (U.S.A.) Inc. Simultaneous calibration heterogeneous immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5723218A (en) 1990-04-16 1998-03-03 Molecular Probes, Inc. Dipyrrometheneboron difluoride labeled flourescent microparticles
US5405975A (en) 1993-03-29 1995-04-11 Molecular Probes, Inc. Fluorescent ion-selective diaryldiaza crown ether conjugates
US5227487A (en) 1990-04-16 1993-07-13 Molecular Probes, Inc. Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5433896A (en) 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5459276A (en) 1994-05-20 1995-10-17 Molecular Probes, Inc. Benzazolylcoumarin-based ion indicators for heavy metals
US5326692B1 (en) 1992-05-13 1996-04-30 Molecular Probes Inc Fluorescent microparticles with controllable enhanced stokes shift
US5648270A (en) 1995-02-06 1997-07-15 Molecular Probes, Inc. Methods of sensing with fluorescent conjugates of metal-chelating nitrogen heterocycles
US5453517A (en) 1992-02-25 1995-09-26 Molecular Probes, Inc. Reactive derivatives of bapta used to make ion-selective chelators
EP0542874A4 (en) 1990-07-25 1994-05-11 Syngene Inc Circular extension for generating multiple nucleic acid complements
AU669489B2 (en) 1991-09-18 1996-06-13 Affymax Technologies N.V. Method of synthesizing diverse collections of oligomers
US5422252A (en) 1993-06-04 1995-06-06 Becton, Dickinson And Company Simultaneous amplification of multiple targets
WO1997019193A2 (en) 1995-11-21 1997-05-29 Yale University Unimolecular segment amplification and detection
WO2001018210A1 (en) * 1999-09-08 2001-03-15 Genentech, Inc. Fibroblast growth factor-19 (fgf-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
EP1071429B1 (en) * 1998-04-17 2002-01-30 Trustees Of Tufts College Map kinase inhibitors in the treatment of disorders caused by tnf-alpha induced lipolysis
US6153432A (en) * 1999-01-29 2000-11-28 Zen-Bio, Inc Methods for the differentiation of human preadipocytes into adipocytes
WO2001075164A2 (en) 2000-03-30 2001-10-11 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference
AU5056501A (en) * 2000-03-31 2001-10-08 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
CA2490261A1 (en) * 2002-06-27 2004-01-08 The University Of Queensland Differentiation modulating agents and uses therefor

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0420081A1 (en) * 1989-09-26 1991-04-03 Takeda Chemical Industries, Ltd. Monoclonal antibody against an acidic FGF protein, its production and use
WO2000071129A1 (en) * 1999-05-21 2000-11-30 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
WO2001049849A1 (en) * 2000-01-05 2001-07-12 Zymogenetics, Inc. Novel fgf homolog zfgf11
WO2001070977A2 (en) * 2000-03-22 2001-09-27 Amgen, Inc. Fibroblast growth factor receptor-like molecules and uses thereof
EP1202065A1 (en) * 2000-10-25 2002-05-02 Aventis Pharma S.A. Net, a transcription factor of the TCF family, as regulator of angiogenic expression.
WO2003099796A1 (en) * 2002-05-23 2003-12-04 Cytopia Pty Ltd Protein kinase inhibitors
WO2004001059A2 (en) * 2002-06-20 2003-12-31 Bristol-Myers Squibb Company Heterocyclic inhibitors of kinases

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
COSIC IRENA ET AL: "In vitro inhibition of the actions of basic FGF by a novel 16 amino acid peptide", MOLECULAR AND CELLULAR BIOCHEMISTRY, vol. 130, no. 1, 1994, pages 1 - 9, XP009062598, ISSN: 0300-8177 *
HAUNER H ET AL: "Effects of epidermal growth factor (EGF), platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) on human adipocyte development and function.", EUROPEAN JOURNAL OF CLINICAL INVESTIGATION FEB 1995, vol. 25, no. 2, February 1995 (1995-02-01), pages 90 - 96, XP000198734, ISSN: 0014-2972, DOI: 10.1111/j.1365-2362.1995.tb01532.x *
KAWAGUCHI NOBUKO ET AL: "De novo adipogenesis in mice at the site of injection of basement membrane and basic fibroblast growth factor", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 95, no. 3, 3 February 1998 (1998-02-03), pages 1062 - 1066, XP002370034, ISSN: 0027-8424 *
KRIEGER-BRAUER HEIDEMARIE I ET AL: "Antagonistic effects of different members of the fibroblast and platelet-derived growth factor families on adipose conversion and NADPH-dependent H-2O-2 generation in 3T3 L1-cells", BIOCHEMICAL JOURNAL, vol. 307, no. 2, 1995, pages 549 - 556, XP002370033, ISSN: 0264-6021 *
MILLER ET AL: "Compensation by fibroblast growth factor 1 (FGF1) does not account for the mild phenotypic defects observed in FGF2 null mice.", MOLECULAR AND CELLULAR BIOLOGY, vol. 20, no. 6, 1 March 2000 (2000-03-01), pages 2260 - 2268, XP055072326, ISSN: 0270-7306 *
ORNITZ D M ET AL: "RECEPTOR SPECIFICITY OF THE FIBROBLAST GROWTH FACTOR FAMILY", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 271, no. 25, 21 June 1996 (1996-06-21), pages 15292 - 15297, XP002919936, ISSN: 0021-9258, DOI: 10.1074/jbc.271.25.15292 *
R. T. BOTTCHER ET AL: "Fibroblast Growth Factor Signaling during Early Vertebrate Development", ENDOCRINE REVIEWS, vol. 26, no. 1, 1 February 2005 (2005-02-01), pages 63 - 77, XP055072332, ISSN: 0163-769X, DOI: 10.1210/er.2003-0040 *
RUSSELL T R ET AL: "CONVERSION OF 3T3 FIBROBLASTS INTO ADIPOSE CELLS: TRIGGERING OF DIFFERENTIATION BY PROSTAGLANDIN F2ALPHA AND I-METHYL-3-ISOBUTYL XANTHINE", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 12, no. 73, 1 December 1976 (1976-12-01), pages 4516 - 4520, XP001079689, ISSN: 0027-8424, DOI: 10.1073/pnas.73.12.4516 *
SASAKI K ET AL: "Actions of acidic fibroblast growth factor fragments on food intake in rats", OBESITY RESEARCH, BATON ROUGE, LA, US, vol. 3, no. Suppl 5, 1 December 1995 (1995-12-01), pages 697S - 706S, ISSN: 1071-7323 *
SASAKI K ET AL: "EFFECTS OF FRIBROBLAST GROWTH FACTROS AND RELATED PEPTIDES ON FOOD INTAKE BY RATS", PHYSIOLOGY AND BEHAVIOR, ELSEVIER SCIENCE LTD., OXFORD, GB, vol. 56, no. 2, 1 January 1994 (1994-01-01), pages 211 - 218, XP000943197, ISSN: 0031-9384, DOI: 10.1016/0031-9384(94)90186-4 *
SCHMIDT ET AL: "Adipose conversion of 3T3-L1 cells in a serum-free culture system depends on epidermal growth factor, insulin-like growth factor I, corticosterone, and cyclic AMP.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 26, 1 September 1990 (1990-09-01), pages 15489 - 15495, XP055072329, ISSN: 0021-9258 *
See also references of WO2004003179A1 *
SERRERO G ET AL: "Prostaglandin F2 alpha inhibits epidermal growth factor binding to cellular receptors on adipocyte precursors in primary culture", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 212, no. 3, 26 July 1995 (1995-07-26), pages 1125 - 1132, XP008081146, ISSN: 0006-291X, DOI: 10.1006/bbrc.1995.2085 *

Also Published As

Publication number Publication date
NZ537208A (en) 2009-02-28
AU2009251219B2 (en) 2013-01-10
AU2003236557B2 (en) 2009-10-01
JP2010215636A (en) 2010-09-30
CA2490261A1 (en) 2004-01-08
WO2004003179A1 (en) 2004-01-08
EP2267117A2 (en) 2010-12-29
EP1539931A1 (en) 2005-06-15
CN1678734B (en) 2012-12-12
CN1678734A (en) 2005-10-05
JP2005535629A (en) 2005-11-24
EP2267117A3 (en) 2011-07-13
AU2009251219A1 (en) 2010-01-28
AU2003236557A1 (en) 2004-01-19

Similar Documents

Publication Publication Date Title
EP1539931A4 (en) Differentiation modulating agents and uses therefor
EP1539941A4 (en) Adzymes and uses thereof
PT2702871T (en) Collagen biofabric and use thereof
GB2384570B (en) Modulators
EP1501544A4 (en) Alcam and alcam modulators
IL154553A0 (en) Urocortin-iii and uses thereof
GB0220214D0 (en) Compounds and their use
SI1551805T1 (en) Substituted gamma-phenyl-delta-lactams and uses related thereto
AU2003232075A8 (en) Modified t lymphocytes and uses therefor
GB0126889D0 (en) Compounds and their uses
IL165112A0 (en) Variant integrinpolypeptides and thereof
AU2003298739A8 (en) Intermedin and its uses
AU2003231827A8 (en) Pseudo-tissues and uses thereof
AU2002364612A8 (en) Methods and materials for modulating enac-beta
GB0102717D0 (en) Cells and uses therefor
AU2003209879A8 (en) Vpr modulators and uses thereof
AU2003302173A8 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
EP1701736A4 (en) Therapeutic agents and uses therefor
AU2003228397A8 (en) Hausp-p53 interaction and uses thereof
AU2003216442A8 (en) Enkurin and uses thereof
AU2003228990A8 (en) Hydroxyphosphonates and phosphonophosphates as apolipoprotein e modulators
GB0218031D0 (en) Compounds and their use
AU2003255232A1 (en) Antigiardial agents and use thereof
AU2004900050A0 (en) Differentiation modulating agents and uses therefor
AU2002367320A8 (en) Methods and materials for modulating task-3

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050127

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1076838

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20060725

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ADIPOGEN PHARMACEUTICALS PTY LIMITED

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ADIPOGEN PHARMACEUTICALS PTY LIMITED

17Q First examination report despatched

Effective date: 20090902

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: VERVA PHARMACEUTICALS PTY

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/18 20060101ALI20130703BHEP

Ipc: A61K 38/18 20060101AFI20130703BHEP

Ipc: C12N 5/077 20100101ALI20130703BHEP

Ipc: G01N 33/74 20060101ALI20130703BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1076838

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140103